Tectonic - Nilai perusahaan marang pendapatan TECX

Tectonic Therapeutic Inc. (TECX) - logo korporat

The financial performance of Tectonic Therapeutic, Inc. (TECX) depends on the success of G protein-coupled receptor trials and the inflow of R&D capital. The EV/Sales multiple trajectory visualizes the trend's stability, where 0.00 serves as the current metric level. High bioengineering costs and FDA patents create significant barriers to entry. The environmental profile is limited by strict adherence to laboratory biosafety during protein synthesis.

TECX (Tectonic) riwayat Rasio nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Tectonic Therapeutic Inc. - rincian analitis lan metrik utama (TECX)

- indikator dhuwit lan arus kas:
Pambiji fundamental perusahaan:Tectonic Therapeutic, Inc.
Produk dadi Tectonic Therapeutic

The development of Tectonic Therapeutic, Inc. (TECX) depends on the successful creation of protein-based drugs and the protection of intellectual property. The effectiveness of these developments directly impacts market capitalization and, consequently, the calculated multiple. This metric measures the total enterprise value, including debt minus cash, relative to sales volume. This allows for an assessment of the asset's fundamental value regardless of financial leverage. The EV/Sales trend for Tectonic Therapeutic, Inc. (TECX) reflects real market demand for the technology.

Pesaing langsung

HLN: Rasio nilai perusahaan marang pendapatan|Kenvue Corp (KVUE) - Rasio nilai perusahaan marang pendapatan|Verona Pharma PLC - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Jyong Biotech Ltd|Multiplikator EV/Sales Ligand Corp|Multiplikator EV/Sales AMRX|Rasio total nilai perusahaan marang pendapatan Perrigo Company plc|Multiplikator EV/Sales ALVO (Alvotech Biopharmaceuticals)|LQDA: Rasio nilai perusahaan marang pendapatan|Galapagos N.V. - Multiplikator EV/Sales|ANIP - Multiplikator EV/Sales|MNKD: Multiplikator EV/Sales|amphastar.com (AMPH) - Multiplikator EV/Sales|PCRX (Pacira Pharmaceuticals) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan ARS Pharmaceuticals, Inc. (SPRY)|Multiplikator EV/Sales TBPH|AQST (Aquestive Therapeutics) - Nilai bisnis marang pendapatan|scPharmaceuticals, Inc. - Nilai perusahaan marang pendapatan|TNXP - Nilai perusahaan marang pendapatan|China SXT Pharmaceuticals, Inc. - Multiplikator EV/Sales|EPRX - Multiplikator EV/Sales|BHST: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan eXoZymes Inc (EXOZ)|ORMP (oramed.com) - Multiplikator EV/Sales|Rasio nilai perusahaan marang pendapatan ENTX (Entera Bio)|Rasio nilai perusahaan marang pendapatan MindWalk (HYFT)|Multiplikator EV/Sales ABVC BioPharma, Inc. (ABVC)|Rasio nilai perusahaan marang pendapatan Cumberland Corp CPIX|QNTM - Nilai perusahaan marang pendapatan|FGEN - Rasio nilai perusahaan marang pendapatan|TELO - Multiplikator EV/Sales|Rani Therapeutics Inc (RANI) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan SNYR|Rasio nilai perusahaan marang pendapatan Rallybio Corp|Rasio nilai perusahaan marang pendapatan LEXX|Multiplikator EV/Sales PULM|PTHL: Nilai perusahaan marang volume dodolan|Multiplikator EV/Sales APM (Aptorum Group Ltd)|LYRA - Nilai perusahaan marang pendapatan|Impact BioMedical Inc - Multiplikator EV/Sales|Nilai perusahaan marang volume dodolan TNFA|YCBD (cbdmd.com) - Nilai perusahaan marang pendapatan|painreform.com - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan CYTO|Rasio nilai perusahaan marang pendapatan LIPO|Rasio nilai perusahaan marang pendapatan optinose.com (OPTN)|PIRS (Pieris Pharma) - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Procaps Group S.A. PROC|Rasio total nilai perusahaan marang pendapatan petrospharma.com (PTPI)|QLI - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Rasio nilai perusahaan marang pendapatan